Compare Consolidated Edison, Inc. (ED) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs Mesoblast Limited — how do they compare? Consolidated Edison, Inc. trades at $106.11 (market cap $38.70B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Consolidated Edison, Inc. is far larger — about 21.4× Mesoblast Limited's market cap, and Consolidated Edison, Inc. pays a 3.36% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and Mesoblast Limited for 14 Days on average.
| ED | MESO | |
|---|---|---|
Market Cap | $38.70B | $1.81B |
Volume | 2,154,810 | 240,620 |
Sector | Utilities | Health |
52-Week High | $115.46 | $20.96 |
52-Week Low | $95.37 | $13.19 |
Typical Hold Time | 75 Days | 14 Days |
Enterprise Value | $65.55B | $1.89B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ED (Consolidated Edison) trades at $105.99, up 0.83% today, near the consensus price target of $106.33. The stock shows a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, 2025 revenue grew to $16.92B with a net income margin of 12.53%, while recent earnings have been mixed with a Q1 2026 miss. The company maintains a solid dividend, with a recent $0.89 payout announced for September 2026, and is highlighted in news for its economic impact in New York and involvement in electric bus infrastructure.
Outlook is balanced; ED offers stability as a utility stock with consistent dividends and moderate growth, but faces risks from debt levels and interest expenses. Analyst sentiment is cautious with 62.96% hold ratings. Key catalysts include the upcoming investor presentation on October 6, 2026, and execution on capital investments. Risks involve regulatory changes and economic sensitivity.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
